Abstract:Non-infectious uveitides (NIUs) encompass a varied group of inflammatory diseases affecting the uvea and adjacent tissues, with evidence suggesting an immune-mediated cause. A correct management of these conditions is essential to prevent substantial and sometimes permanent visual loss and the development of ocular complications. Although immunosuppressive drugs (ISDs) have shown effectiveness in achieving a sustained control of the inflammatory process, not all patients achieve a satisfactory response.To identify factors affecting the response rate to ISDs in subjects with NIUs.Longitudinal retrospective study, with patients collected from the Hospital Clinico San Carlos Uveitis Clinic, included from 1991 until December 2018, and followed-up until December 2019. Patients entered the study at ISD prescription and were followed-up until a) the achievement of a good therapeutic response (GTR), b) ISD treatment change (withdrawal of the prescribed ISD and/or addition of a new ISD), c) 12 months of follow-up, or d) loss of follow-up or end of the study (December 31th, 2019). GTR was defined as the complete resolution of the eye inflammatory manifestations and oral corticosteroid ≤10 mg of prednisone equivalent a day. Furthermore, this situation had to be maintained in at least two consecutive visits spanned at least 28 days. Kaplan-Meier (KM) curves were set to account for GTR. Associated demographic, clinical and treatment-related factors were analyzed using bivariate and multivariate Cox robust regression models. Different models were compared using the Akaike Information Criteria, to select the fittest model to the data. Proportional hazard assumption was tested using Schoenfeld residuals and the scaled Schoenfeld residuals. In case a variable or certain category of a categorical variable were non-proportional, they were included in the Cox models with a time-varying effect, in case the interaction with time was significant (p<0.05).73 patients (100 episodes of ISD prescription) were analyzed. In 44 episodes, a GTR was achieved (incidence rate 102.0 [95% Confidence Interval (CI): 75.9 to 137.1] per 100 patient-years). Figure 1 shows the KM curve for GTR. In the bivariate analysis, several variables showed a significant association with GTR, including gender, diagnosis of Behçet Disease, prescription of Cyclosporine A (CYA), number of previously prescribed ISDs, previous use of the same ISD, previous discontinuation of a ISD due to inefficacy, higher systemic corticosteroid use in the previous year before ISD prescription, presence of macular edema (ME), and longer intermediate and posterior activity before ISD prescription. Table 1 shows the results of the multivariate analysis. Prescription of CYA was associated with a higher hazard of GTR, compared with the use of other ISDs (methotrexate, azathioprine or biologic drugs). In addition, the higher dosage of oral corticosteroids used in the previous year before ISD prescription, the lower the hazard of achieving a GTR. Finally, presence of ME at prescription was associated with lower hazard of GTR, although this risk diminished with time.Table 1.Multivariate Cox robust regression to analyze variables independently associated with the achievement of good therapeutic response.VariableHR (95% CI)p valueSchoenfel test p valueCYA prescription2.04 (1.14-3.67)0.0170.56Number of previous ISDs0Reference--112.61 (2.07-76.73)5.9x10-30.001≥23.54 (1.55-8.05)2.6x10-30.561 previous ISD X Time0.01 (0.001-1.00)0.005Higher oral corticosteroids dosage (mg) in the previous year0.98 (0.97-0.99)0.0130.83Macular edema0.14 (0.04-0.45)9.3x10-30.001Macular edema X Time14.20 (1.55-103.10)0.019Figure 1.Kaplan-Meier failure curves representing good therapeutic response after immunosuppressive drug prescription for non-infectious uveitis.We have identified several variables associated with therapeutic response to ISDs in NIUs patients.None declared

Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI©

Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis

An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

Quantitative Characterization Of Autoimmune Uveoretinitis In An Experimental Mouse Model

Correlation and Level of Agreement between the Ocular Surface Disease Index and the Symptom Assessment in Dry Eye Questionnaires: A Survey-Based Study

Clinical and Functional Evaluation of Ocular Inflammatory Disease Using the Model of Experimental Autoimmune Uveitis.

Psychometric evaluation of the National Eye Institute Visual Function Questionnaire and Visual Function Questionnaire Utility Index in patients with non-infectious intermediate and posterior uveitis

Anterior Vitreous Objective Assessment in Uveitis: An Anterior Segment Swept Source Optical Coherence Tomography Study

Vitreoretinal Interface Cells Correlate In Vivo With Uveitis Activity and Decrease With Anti-Inflammatory Treatment

Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study

Knowledge and Current Practices in Monogenic Uveitis: An International Survey by IUSG and AIDA Network

Utilisation of composite endpoint outcome to assess efficacy of tocilizumab for non-infectious uveitis in the STOP-Uveitis Study

Appropriateness of Questionnaires for the Diagnosis and Monitoring Treatment of Dry Eye Disease

Unraveling the Spectrum of Uveitis: Insights from an Epidemiological Study in a National Referral Center in Northern Italy

Uveitis and Dry Eye Disease in Children: A Cross-Sectional Comparative Study

P280 Comparative responsiveness of disease activity indices in moderately-to-severely active Ulcerative Colitis: a post-hoc analysis of the UNIFI trial

POS1354 ANALYSIS OF FACTORS ASSOCIATED WITH GOOD THERAPEUTIC RESPONSE TO IMMUNOSUPPRESSIVE DRUGS IN PATIENTS WITH NON-INFECTIOUS UVEITIS: A SURVIVAL ANALYSIS

Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)

Predictors of Therapy Success in Weekly Adalimumab for Refractory Uveitis: A Retrospective Cohort Study

Prevalence and risk factors for complicated immuno-mediated uveitis: experience in a tertiary hospital

Tear and Plasma Levels of Cytokines in Patients with Uveitis: Search for Active Disease Biomarkers